Nitric oxide solution

Drug Profile

Nitric oxide solution

Alternative Names: RespiNOS

Latest Information Update: 01 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Barts and The London NHS Trust; Queen Mary Medical School
  • Developer Barts and The London NHS Trust; Edixomed; Queen Mary Medical School
  • Class Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Diabetic foot ulcer; Pneumonia
  • No development reported Bronchiectasis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Aug 2013 Clinical trials in Diabetic foot ulcer in United Kingdom (Topical) before August 2013
  • 30 Dec 2011 No development reported - Phase-I for Bronchiectasis in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top